

66. B. K. Piao, et al. "Impact of complementary mistletoe extract treatment on quality of life in breast, ovarian, and non-small cell lung cancer patients: A prospective randomized controlled clinical trial," *Anticancer Research*, 24 no. 1 Jan.-Feb. 2004:303-9.
67. F. Pelzer, et al. "Complementary treatment with mistletoe extracts during chemotherapy: Safety, neutropenia, fever, and quality of life assessed in a randomized study," *J. Altern. Complement Med.*, 2018;24:954-961. DOI: 10.1089/acm.2018.0159.
68. V. F. Semiglazov, et al. "Quality of life is improved in breast cancer patients by standardised mistletoe extract PS76A2 during chemotherapy and follow-up: A randomised, placebo-controlled, double-blind, multicentre clinical trial," *Anticancer Research* 26 no. 2B (Mar.-Apr., 2006):1519-29.

CHAPTER 3

1. G. Bacci, et al., "Treatment and outcome of recurrent osteosarcoma: Experience at Rizzoli in 235 patients initially treated with neoadjuvant chemotherapy," *Acta. Oncologica*, vol. 44, no. 7, pp. 748-55, 2005.
2. S. S. Bielack, B. et al., "Second and subsequent recurrences of osteosarcoma: presentation, treatment, and outcomes of 249 consecutive cooperative osteosarcoma study group patients," *Journal of Clinical Oncology*, vol. 27, no. 4, pp. 557-65, 2009.
3. A. Briccoli, et al. "High-grade osteosarcoma of the extremities metastatic to the lung: long-term results in 323 patients treated combining surgery and chemotherapy, 1985- 2005," *Surgical Oncology*, vol. 19, no. 4, pp. 193-99, 2010.
4. E. Tirtei, et al., "Survival after second and subsequent recurrences in osteosarcoma: A retrospective multicenter analysis," *Tumori Journal*, vol. 104, no. 3, pp. 202-06, 2018.
5. A. A. Senerchia, et al., "Results of a randomized, prospective clinical trial evaluating metronomic chemotherapy in nonmetastatic patients with high-grade, operable osteosarcomas of the extremities: A report from the Latin American group of osteosarcoma treatment," *Cancer*, vol. 123, no. 6, pp. 1003-10, 2017.
6. R. Kebudi, et al. "Oral etoposide for recurrent/progressive sarcomas of childhood," *Pediatric Blood and Cancer*, vol. 42, no. 4, pp. 320-24, 2004.
7. S. S. Bielack, et al., "Second and subsequent recurrences of osteosarcoma: Presentation, treatment, and outcomes of 249 consecutive cooperative osteosarcoma study group patients," *Journal of Clinical Oncology*, vol. 27, no. 4, pp. 557-65, 2009.
8. G. Bacci, et al., "Treatment and outcome of recurrent osteosarcoma: experience at Rizzoli in 235 patients initially treated with neoadjuvant chemotherapy," *Acta Oncologica*, vol. 44, no. 7, pp. 748-55, 2005.
9. W. B. Coley, "Contribution to the knowledge of sarcoma," *Annals of Surgery*, vol. 14, pp. 199-222, 1891.

10. S. Kleinsimon, et al. "ViscumTT induces apoptosis and alters IAP expression in osteosarcoma in vitro and has synergistic action when combined with different chemotherapeutic drugs," *BMC Complementary and Alternative Medicine*, vol. 17, no. 1, p. 26, 2017.
11. M. op den Winkel, et al. "Prognosis of patients with hepatocellular carcinoma: Validation and ranking of established staging-systems in a large western HCC-cohort," *PLoS One*, 2012;7(10):e45066. doi:10.1371/journal.pone.0045066.
12. A. Tang, et al. "Epidemiology of hepatocellular carcinoma: Target population for surveillance and diagnosis," *Abdom. Radiol. (NY)*, 2018 Jan;43(1):13–25. doi: 10.1007/s00261-017-1209-1. PMID: 28647765.
13. R. S. Finn, et al. "Atezolizumab plus Bevacizumab in unresectable hepatocellular carcinoma," *N. Engl. J. Med.*, 2020;382:1894–905. DOI: 10.1056/NEJMoa1915745.
14. L. Rimassa and A. Santoro. "Sorafenib therapy in advanced hepatocellular carcinoma: The SHARP trial," *Expert Review of Anticancer Therapy*, vol. 9,6 (2009): 739–45. doi:10.1586/era.09.41.
15. M. Kudo. "Targeted and immune therapies for hepatocellular carcinoma: Predictions for 2019 and beyond," *World J. Gastroenterology*, vol. 25,7 (2019): 789–807. doi:10.3748/wjg.v25.i7.789.
16. G. da Motta, et al. "Hepatocellular carcinoma: Review of targeted and immune rherapies," *J. Gastrointestinal Cancer*, vol. 49,3 (2018): 227–36. doi:10.1007/s12029-018-0121-4.
17. M. Pinter and M. Peck-Radosavljevic. "Review article: Systemic treatment of hepatocellular carcinoma," *Alimentary Pharmacology and Therapeutics*, vol. 48,6 (2018): 598–609. doi:10.1111/apt.14913.
18. R. S. Finn, et al. "Pembrolizumab as second-line therapy in patients with advanced hepatocellular carcinoma in keynote-240: A randomized, double-blind, phase III trial," *J. Clinical Oncology*, vol. 38,3 (2020): 193–202. doi:10.1200/JCO.19.01307.
19. T. Yau, et al, "LBA38_PR – CheckMate 459: A randomized, multi-center phase III study of nivolumab (NIVO) vs sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced hepatocellular carcinoma (aHCC)," *Annals of Oncology*, vol. 30, supp. 5, Oct. 2019, 874–75.
20. A. Villanueva. "Hepatocellular carcinoma," *N. Engl. J. Med.*, Apr. 2019, 11;380(15):1450–1462. doi: 10.1056/NEJMr1713263. PMID: 30970190.
21. G. Falkson and W. Burger. "A phase II trial of vindesine in hepatocellular cancer," *Oncology*, Jan.–Feb. 1995;52(1):86–7. doi: 10.1159/000227434. PMID: 7800350.
22. S. Okada, et al. "A phase 2 study of cisplatin in patients with hepatocellular carcinoma," *Oncology*. 1993;50(1):22–6. doi: 10.1159/000227142. PMID: 7678453.
23. R. Wierzbicki, et al. "Phase II trial of chronic daily VP-16 administration in unresectable hepatocellular carcinoma (HCC)," *Ann. Oncol.*, 1994 May;5(5):466–7. doi: 10.1093/oxfordjournals.annonc.a058882. PMID: 8075054.
24. T. Yoshida, et al. "Phase II trial of mitoxantrone in patients with hepatocellular carcinoma," *Eur. J. Cancer Clin. Oncol.*, Dec.

- 1988;24(12):1897-98. doi: 10.1016/0277-5379(88)90104-6. PMID: 2851445.
25. R. Lee, et al. "Mistletoe extract viscum fraxini-2 for treatment of advanced hepatocellular carcinoma: A case series," *Case Rep. Oncol.*, 2021;14:224-231. doi: 10.1159/000511566.
26. P. Yang P, et al. "Clinical application of a combination therapy of lentinan, multi-electrode RFA and TACE in HCC," *Advances in Therapy*. 25 (8): 787-94. (Aug. 2008). doi:10.1007/s12325-008-0079-x. PMID 18670743. S2CID 33140754.
27. H. Nimura, et al. "S-1 combined with lentinan in patients with unresectable or recurrent gastric cancer," *Gan. to Kagaku Ryoho* (in Japanese), (Jun. 2006). 33 (1): 106-9. PMID 16897983.
28. H. Nakano, et al. "A multi-institutional prospective study of lentinan in advanced gastric cancer patients with unresectable and recurrent diseases: Effect on prolongation of survival and improvement of quality of life Kanagawa Lentinan Research Group," *Hepatogastroenterology*. (1999). 46 (28): 2662-8. PMID 10522061.
29. K. Oba, et al. "Individual patient based meta-analysis of lentinan for unresectable/recurrent gastric cancer," *Anticancer Research* 29 (7): 2739-45. (July 2009). PMID 19596954.
30. S. Hazama, et al. "Efficacy of orally administered superfine dispersed lentinan (β -1,3-glucan) for the treatment of advanced colorectal cancer," *Anticancer Research* 29 (7): 2611-2617. (July 2009). PMID 19596936.
31. H. Kataoka, et al. "Lentinan with S-1 and paclitaxel for gastric cancer chemotherapy improve patient quality of life," *Hepatogastroenterology* 56 (90): 547-50. (2009). PMID 19579640.
32. N. Isoda, et al. "Clinical efficacy of superfine dispersed lentinan (β -1,3-glucan) in patients with hepatocellular carcinoma," *Hepatogastroenterology* 56 (90): (2009). 437-41. PMID 19579616.
33. K. Shimizu, et al. "Efficacy of oral administered superfine dispersed lentinan for advanced pancreatic cancer," *Hepatogastroenterology* 56 (89): 240-44. (2009). PMID 19453066.
34. Y. Zhang, et al. "Lentinan as an immunotherapeutic for treating lung cancer: A review of 12 years clinical studies in China," *J. Cancer Res. Clin. Oncol.*, 2018 Nov;144(11):2177-86. doi: 10.1007/s00432-018-2718-1; epub 2018 Jul 24. PMID: 30043277.
35. Portions of this study summary originally appeared at www.mistletoe-therapy.org (used with permission).
36. Some of these conclusions originally appeared at www.mistletoe-therapy.org (used with permission).
37. F. Pelzer, et al. "Complementary treatment with mistletoe extracts during chemotherapy: Safety, neutropenia, fever, and quality of life assessed in a randomized study," *J. Altern. Complement Med.*, 2018;24:954-961. DOI: 10.1089/acm.2018.0159.
38. V. Bocci. "Mistletoe (*Viscum album*) lectins as cytokine inducers and immunoadjuvant in tumor therapy: A review," *J. Biol. Reg. Homeos. Agents*, 7: 1-6, 1993.

39. U. Mengs, et al. "Mistletoe extracts standardized to mistletoe lectins in oncology: Review on current status of preclinical research," *Anticancer Res.*, 22: 1399-1408, 2002.
40. H. Stauder and E. D. Kreuser. "Mistletoe extracts standardised in terms of mistletoe lectins (MLI) in oncology: Current state of clinical research," *Onkologie* 25: 374-80, 2002.
41. D. F. Cella, et al. "The functional assessment of cancer therapy (FACT) scale: Development and validation of the general measure," *J. Clin. Oncol.*, 11: 570-79, 1993.
42. O. Krauss and R. Schwarzw. "FACT—Functional assessment of cancer therapy," in J. Schumacher, et al. (eds.). *Diagnostische Verfahren zu Lebensqualität und Wohlbefinden*, Göttingen: Hogrefe-Verlag, 2003, pp. 97-101.
43. P. C. O'Brien. "Procedures for comparing samples with multiple end-points," *Biometrics*, 40: 1079-87, 1984.
44. A. Coate, et al. "On the receiving end—III: Measurement of quality of life during cancer chemotherapy," *Ann. Oncol.*, 1: 213-17, 1990.
45. M. Pandey, et al. "Quality of life in patients with early and advanced carcinoma of the breast," *Eur. J. Surg. Oncol.*, 26: 20-24, 2000.
46. C. Hürny, et al. "Impact of adjuvant therapy on quality of life in women with node-positive operable breast cancer: International Breast Cancer Study Group," *Lancet*, 347: 1279-84, 1996.
47. Ibid.
48. C. Hürny, et al. "Quality of life assessment in the International Breast Cancer Study Group: Past, present, and future: Recent results," *Cancer Res.*, 152: 390-95, 1998.
49. M. Babjuk, et al. "EAU Guidelines on non-muscle-invasive urothelial carcinoma of the bladder: Update 2013," *Eur. Urol.*, 2013; 64: 639.
50. R. Sylvester, et al. "A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage TaT1 bladder cancer: A meta-analysis of published results of randomized clinical trials," *J. Urol.*, 2004; 171: 2186.
51. R. Sylvester, et al. "High-grade Ta urothelial carcinoma and carcinoma in situ of the bladder," *Urology*, 2005; 66: 90.
52. R. L. Deresiewicz, et al. "Fatal disseminated mycobacterial infection following intravesical BCG," *J. Urol.*, 1990; 144: 1331.
53. D. L. Lamm, et al. "Incidence and treatment of complications of bacillus Calmette-Guerin intravesical therapy in superficial bladder cancer," *J. Urol.*, 1992; 147: 596.
54. M. Babjuk, et al. *Guidelines on non-muscle invasive bladder cancer (TaT1 and CIS)*, Arnhem, The Netherlands: European Association of Urology, 2013.
55. Per M. Debus, updates on EAU Guidelines may be found here: M. Babjuk, et al. "European Association of Urology guidelines on non-muscle-invasive bladder cancer (TaT1 and carcinoma in situ), 2019 update," *Eur. Urol.*, Nov. 2019;76(5):639-657. doi: 10.1016/j.eururo.2019.08.016. Epub Aug. 20, 2019. PMID: 31443960.

56. Assertions in this paragraph are based on authors' awareness of more recent studies (includes updates beyond the scope of what Tröger et. al. 2013).
57. A. Lambert, et al. "An update on treatment options for pancreatic adenocarcinoma," *Ther. Adv. Med. Oncol.*, 2019, vol. 2: 1–43. DOI: 10.1177/1758835919875568.
58. M. Rostock, et al. "Anticancer activity of a lectin-rich mistletoe extract injected intratumorally into human pancreatic cancer xenografts," *Anticancer Research*, 2005;25(3B): 1969–75.
59. H. Matthes, et al. "Intratumorale applikation von Viscum album L. (Mistelgesamtextrakt; Helixor M) in der therapie des inoperablen pankreas-karzinom" [Intratumoral application of Viscum album L. (whole mistletoe extract; Helixor M) as therapy for inoperable pancreatic cancer], *Z. Gastroenterology*, 2007;45, <http://dx.doi.org/10.1055/s-2007-988162>.
60. Much of this study summary originally appeared at www.mistletoe-therapy.org (used with permission).
61. K. Wode, et al. "Efficacy of mistletoe extract as a complement to standard treatment in advanced pancreatic cancer: Study protocol for a multicentre, parallel group, double-blind, randomised, placebo-controlled clinical trial (MISTRAL)," *Trials*, 21, 783 (2020). <https://doi.org/10.1186/s13063-020-04581-y>.
62. T. Nguyen, et al. "Cost and survival analysis before and after implementation of Dana-Farber clinical pathways for patients with stage IV non-small-cell. lung cancer," *J. Oncol. Pract.*, 2017; 13:e346±e352. <https://doi.org/10.1200/JOP.2017.021741> PMID: 28260402.
63. Administration USFD. Pembrolizumab (KEYTRUDA) Checkpoint Inhibitor. 2016. Available from: <https://www.fda.gov/drugs/informationondrugs/approveddrugs/ucm526430.htm>.
64. Administration USFD. FDA expands approved use of Opdivo in advanced lung cancer. 2015. Available from: <https://www.fda.gov/newsevents/newsroom/pressannouncements/ucm466413.htm>.
65. N. A. Rizvi, et al. "Nivolumab in combination with platinum-based doublet chemotherapy for first-line treatment of advanced non-small-cell lung cancer," *J. Clin. Oncol.*, 2016; 34:2969–79. <https://doi.org/10.1200/JCO.2016.66.9861> PMID: 27354481.
66. T. Ostermann, et al. "A systematic review and meta-analysis on the survival of cancer patients treated with a fermented viscum album L. extract (Iscador): An update of findings," *Complement. Med. Res.*, 2020;27(4):260–71. English. doi: 10.1159/000505202. Epub 2020 Jan 10. PMID: 31927541.
67. Portions of this study summary originally appeared at www.mistletoe-therapy.org (used with permission).
68. R. Willemze, et al. "WHO-EORTC classification for cutaneous lymphomas," *Blood*, 2005 May 15;105(10):3768–85.
69. P. T. Bradford, et al. "Cutaneous lymphoma incidence patterns in the United States: A population-based study of 3,884 cases." *Blood*, 2009 May 21;113(21):5064–73.